

28 ~~33~~. A composition suitable for the treatment of cancer which comprises a therapeutic effectively amount of <sup>a</sup> ~~at least one~~ compound as set forth in Claim 1, and a pharmaceutically acceptable carrier or excipient.

29 ~~34~~. The composition of Claim <sup>28</sup> ~~33~~, wherein said carrier or excipient is selected from the group consisting of lactose, glucose, starch, calcium carbonate, kaoline, crystalline cellulose, silicic acid, water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose, polyvinyl pyrrolidone, dried starch, sodium alginate, powdered agar, calcium carmelose, a mixture of starch and lactose, sucrose, butter, hydrogenated oil, a mixture of a quarternary ammonium base and sodium lauryl sulfate, glycerine and starch, lactose, bentonite, colloidal silicic acid, talc, stearates, and polyethylene glycol.

30 ~~35~~. The composition of Claim <sup>28</sup> ~~33~~, which is in the form of a dosage formulation selected from the group consisting of a tablet, pill, powder, solution, suspension, emulsion, granule, capsule, injectable solution or suspension, and suppository.

31 ~~36~~. A pharmaceutical composition which comprises a pharmaceutically effective amount of <sup>a</sup> ~~at least one~~ compound according to Claim 1.

B!  
Amended  
32 ~~37~~ <sup>31</sup> The composition of Claim ~~36~~<sup>31</sup>, which is a pharmaceutically acceptable formulation selected from the group consisting of a tablet, pill, powder, solution, suspension, emulsion, granule, capsule, injectable solution or suspension, and suppository.--

**REMARKS:**

Entry of the foregoing amendments, reconsideration and reexamination of the subject application, as amended, pursuant to and consistent with 37 C.F.R. §1.112, and in light of the remarks which follow, are respectfully requested.

By the present amendments, Claims 31 and 32 have been cancelled in favor of new Claims 33 through 37. These amendments are made in order to better conform these claims to U.S. practice. In particular, the claims now are directed to a pharmaceutical or anti-tumor composition which comprises an anti-tumor or pharmaceutically effective amount of at least one compound according to Claim 1 in combination with a pharmaceutically acceptable carrier. The dependent claims further provide for specific dosage formulations and pharmaceutically acceptable carriers which find support at page 58 of the subject application.

Also, corrections to two structures are made at pages 41 and 42. These changes correct obvious errors based on the name of the compounds.